braf-metastatic-nsclc-hcp-rx.com · Обнаружен 1 ч назад
See safety information of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib), a combination treatment for adults with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.